التفاصيل البيبلوغرافية
| العنوان: |
Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient‐reported outcome measures. |
| المؤلفون: |
de Wijs, L.E.M., Fujimoto, R.F.T., Andrinopoulou, E.R., Nijsten, T., Hijnen, D., Kataoka, Y. |
| المصدر: |
British Journal of Dermatology; Sep2021, Vol. 185 Issue 3, p555-562, 8p |
| مصطلحات موضوعية: |
PATIENT reported outcome measures, DUPILUMAB, ATOPIC dermatitis, JAPANESE people, COHORT analysis |
| مصطلحات جغرافية: |
NETHERLANDS, JAPAN |
| مستخلص: |
Summary: Background: Dupilumab was equally effective among all racial subgroups in clinical trials, but a direct comparison in daily practice is lacking. Objectives: To investigate the effectiveness of dupilumab in patients with atopic dermatitis (AD) in the Netherlands and Japan over 80 weeks of treatment. Methods: A longitudinal comparative cohort study was conducted in patients with AD who were treated with dupilumab in daily practice. We used linear mixed‐effects models to determine changes over time. Results: We found statistically significant differences in sex, disease onset, body mass index and therapeutic history between Dutch (n = 208) and Japanese (n = 153) patients. The baseline Eczema Area and Severity Index (EASI) score was higher in Japanese patients (23·8 vs. 14·8), while baseline Patient‐Reported Outcome Measures (PROMs) were higher in Dutch patients. EASI scores decreased quickly to a level indicating 'mild disease' (EASI < 7), and remained low in both countries. However, PROMs showed different trajectories with better scores in Japan. Conclusions: Dupilumab showed significant, comparable and sustained improvement of EASI scores in Japanese and Dutch patients. However, we found striking differences in the effect on PROMs between the countries, with a better outcome in Japanese patients. What is already known about this topic?In clinical trials, dupilumab was found to be equally effective among all racial subgroups; however, a direct comparison in daily practice between patients with atopic dermatitis (AD) in Japan and the Netherlands is currently lacking.Although phenotypical and immunological differences between races are described for AD, literature about the racial differences in coping mechanisms and the perception of disease in AD is lacking. What does this study add? This study showed a significant improvement of disease severity in both Japanese and Dutch patients with AD during dupilumab treatment in daily practice.In addition to racial disease‐specific differences, healthcare system‐ or culture‐related characteristics might contribute to differences in physician‐ and patient‐reported outcome measures (PROMs) between countries. What are the clinical implications of the work? Consideration of PROMs and healthcare system‐ or culture‐related characteristics, in addition to disease severity measures including the Eczema Area and Severity Index, is of added value in the evaluation of treatment effectiveness in clinical studies and in daily practice. Linked Comment: A. Taïeb and N. Katoh. Br J Dermatol 2021; 185:479–480. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder